Recent studies have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and DA signaling. While GCGR stimulators are increasingly employed for addressing type 2 diabetes mellitus, their potential effects on reinforcement ci